Cipher Pharmaceuticals (TSE:CPH)
TSX:CPH
Want to see TSE:CPH full AI Analyst Report?
CPH Stock Chart & Stats
C$14.90
C$0.11(0.75%)
At close: 4:00 PM EST
C$14.90
C$0.11(0.75%)
Day’s Range― - ―
52-Week RangeC$11.87 - C$20.56
Previous CloseN/A
Volume17.82K
Average Volume (3M)26.25K
Market Cap
C$427.76M
Enterprise ValueC$305.12M
Total Cash (Recent Filing)C$6.41M
Total Debt (Recent Filing)C$428.30K
Price to Earnings (P/E)13.7
Beta0.50
Next Earnings
Aug 06, 2026EPS Estimate
0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,281,181
10 Day Avg. Volume28,238
30 Day Avg. Volume26,255
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$22.00Price Target Upside47.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.88
Revenue Forecast (FY)C$53.41M
Bulls Say, Bears Say
Bulls Say
High Profitability / Net MarginsSustained, very high trailing net margins indicate durable pricing power and attractive product economics in Cipher's specialty dermatology portfolio. Such margins support reinvestment, cover fixed commercial costs and provide a buffer for R&D or M&A, underpinning long‑term cash generation and shareholder returns.
Strong Free Cash Flow & Cash ConversionRobust free cash flow growth and near 1:1 cash conversion to reported earnings point to high earnings quality and efficient working capital. This durable cash generation supports organic investment, downstream commercialization and optionality for licensing, dividends or selective acquisitions without needing frequent external financing.
Conservative Balance Sheet And Healthy ROEVery low leverage and a materially expanded equity base provide financial flexibility to fund launches, absorb shocks and pursue licensing or bolt-on deals. Mid‑20% ROE demonstrates the business converts capital into returns efficiently, a structural advantage for supporting long‑term growth initiatives with limited refinancing risk.
Bears Say
Profitability VolatilityHistorical swings in margins and net income suggest results may be influenced by one‑off items, product mix shifts or timing of licensing revenue. That variability complicates forecasting, makes sustainable margin assumptions less reliable and raises execution risk when planning launches, pricing strategies or shareholder distributions.
Swinging Debt LevelsMaterial year-to-year changes in debt indicate the capital structure can shift quickly, which may reflect episodic financing for deals or working capital. Such swings can raise refinancing, covenant and interest‑cost risks if recurring, reducing predictability of financial flexibility during multi‑period strategic plans.
Small Commercial Scale / Partner DependenceCipher runs a lean commercial footprint (very small employee base) and relies on partners outside Canada. That limits in‑house scale for launches and places execution risk on partners' capabilities and negotiated economics, potentially constraining durable market share gains and making growth more dependent on partnership performance.
Cipher Pharmaceuticals News
CPH FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was C$11.87 and its highest was C$20.56 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is C$427.76M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 77 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported C$0.328 earnings per share for the quarter, beating the consensus estimate of C$0.185 by C$0.144.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.28.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,281,181 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of C$0.328 in its last earnings report, beating expectations of C$0.185. Following the earnings report the stock price went up 10.464%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:CPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$22.00 (47.65% Upside)
C$22.00 (47.65% Upside)
Insider Transactions
Sold Shares
Worth C$129.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.29%
12-Months-Change
Fundamentals
Return on Equity
25.69%
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.
CPH Company Deck
CPH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all TSE:CPH earnings summariesCPH Stock 12 Month Forecast
Average Price Target
C$22.00
▲(47.65% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Options Prices
Currently, No data available
---